MENU
+Compare
ABUS
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$3.22
Change
-$0.02 (-0.62%)
Capitalization
616.72M

ABUS Arbutus Biopharma Corp Forecast, Technical & Fundamental Analysis

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases... Show more

Industry: #Biotechnology
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ABUS with price predictions
Jul 25, 2025

ABUS in upward trend: price may jump up because it broke its lower Bollinger Band on June 26, 2025

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 35 cases where ABUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where ABUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 25, 2025. You may want to consider a long position or call options on ABUS as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABUS just turned positive on July 23, 2025. Looking at past instances where ABUS's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 220 cases where ABUS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

ABUS moved below its 50-day moving average on June 25, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ABUS crossed bearishly below the 50-day moving average on July 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.788) is normal, around the industry mean (18.053). P/E Ratio (0.000) is within average values for comparable stocks, (59.920). ABUS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.580). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (95.238) is also within normal values, averaging (280.104).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ABUS is expected to report earnings to fall 66.15% to -4 cents per share on July 31

Arbutus Biopharma Corp ABUS Stock Earnings Reports
Q2'25
Est.
$-0.04
Q1'25
Missed
by $0.03
Q4'24
Beat
by $0.02
Q3'24
Missed
by $0.01
Q2'24
Missed
by $0.01
The last earnings report on May 14 showed earnings per share of -12 cents, missing the estimate of -10 cents. With 420.86K shares outstanding, the current market capitalization sits at 616.72M.
A.I. Advisor
published General Information

General Information

a developer of drugs to improve the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
701 Veterans Circle
Phone
+1 267 469-0914
Employees
73
Web
http://www.arbutusbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GHAYX43.200.02
+0.05%
VanEck Global Resources Fund Y
FEQTX29.74N/A
N/A
Fidelity Equity Dividend Income
DCINX19.00N/A
N/A
Dunham International Stock C
SXPCX51.71N/A
N/A
DWS S&P 500 Index C
HSZYX6.75N/A
N/A
NexPoint Climate Tech Y

ABUS and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with IDYA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
-0.62%
IDYA - ABUS
48%
Loosely correlated
-1.33%
DNLI - ABUS
44%
Loosely correlated
-4.47%
IMVT - ABUS
44%
Loosely correlated
-7.48%
ARRY - ABUS
43%
Loosely correlated
+3.44%
AXON - ABUS
42%
Loosely correlated
+3.63%
More